NextFin News - Jim Cramer’s Charitable Trust increased its stake in Johnson & Johnson on Monday, purchasing 50 shares at approximately $221.43 as the healthcare giant’s stock fell amid a broader sector rotation. The trade brings the Trust’s total holding to 340 shares, raising its portfolio weighting from 1.62% to 1.9%. The move comes as healthcare remains one of the few laggards in a 2026 market dominated by artificial intelligence and technology, with the sector joining financials as the only major groups down for the year.
Cramer, the host of CNBC’s "Mad Money" and a long-time advocate for diversified, blue-chip investing, has maintained a consistently constructive view on Johnson & Johnson despite its recent underperformance. His investment style often emphasizes "scaling into" high-quality companies during periods of temporary technical weakness. By lowering the Trust’s average cost basis, Cramer is betting that the market’s current fixation on AI has left fundamentally sound pharmaceutical and medical technology leaders undervalued. This contrarian stance is a hallmark of Cramer’s charitable trust strategy, which frequently targets "out-of-favor" stocks with strong cash flows and dividend histories.
The immediate pressure on the healthcare sector on Monday was attributed to external macroeconomic shifts rather than company-specific failures. A surge in oil prices and a corresponding climb in interest rates followed reports of a potential setback in U.S.-Iran peace deal negotiations, prompting investors to exit defensive positions. Johnson & Johnson’s stock has retreated roughly 3% since early May, a decline that Cramer views as a buying opportunity rather than a signal of structural decay. The company is currently navigating a transition period following its Kenvue spinoff, focusing its resources on its Innovative Medicine and MedTech divisions.
While Cramer’s move reflects confidence, it does not represent a unanimous Wall Street consensus. The healthcare sector faces significant headwinds, including the "patent cliff" for blockbuster drugs like Stelara and ongoing litigation regarding legacy products. Some analysts remain cautious, noting that while the company’s Q1 2026 sales reached $24.1 billion—beating estimates—the transition to next-generation therapies must be flawless to offset the loss of exclusivity for older treatments. The market’s current preference for high-growth tech names also means that value-oriented stocks like Johnson & Johnson may continue to trade sideways if capital remains concentrated in the semiconductor and software industries.
The bull case for the stock rests heavily on its research and development pipeline. Over the weekend, at the 2026 American Society of Clinical Oncology meeting, the company presented encouraging data for Rybrevant in treating advanced head and neck cancer and Erleada for prostate cancer. Analysts at Leerink noted on Monday that these treatments could potentially become the standard of care in their respective fields. Furthermore, the recent approval of Icoytde, an oral IL-23 inhibitor for plaque psoriasis, is expected to be a significant revenue driver. These clinical milestones provide the fundamental support for Cramer’s thesis that the company’s long-term growth outlook remains bright despite the short-term noise of the 2026 bull market.
Explore more exclusive insights at nextfin.ai.
